Abstract: The process for the diagnosis, early detection and prognosis of the clinical development of autosomal-dominant polycystic kidney disease (ADPKD) comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: A process for diagnosing vascular diseases (VD), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 526, which are characterized by values for the molecular masses and migration times (CE times).

Abstract: A method for the diagnosis of prostate cancer, comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the polypeptide marker is selected from markers 1 to 44 and 52 to 78 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 45 to 51 and 79 to 115 (amplitude markers), wherein said sample is a urine sample or seminal fluid sample.

Abstract: A method for the diagnosis of bladder cancer (BC) and/or for determining a tumor stage of bladder cancer, comprising the step of determining the presence or absence or amplitude of at least six polypeptide markers in a sample, wherein said polypeptide markers are selected from markers 1 to 836, which are characterized by the values for the molecular masses and migration times (CE time).

Abstract: A method for recognizing rejection after a kidney transplantation (NTx), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 242 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 243 to 767 (amplitude markers), which are characterized by the values for the molecular masses and migration times (CE time).

Abstract: Process for normalizing the concentration of at least one analyte in a urine sample, comprising the following steps: a) determining the concentration of at least one analyte; b) determining the concentration of at least one collagen or collagen fragment; c) normalizing the concentration of said at least one analyte relative to the concentration of said at least one collagen or collagen fragment.

Abstract: A method for the diagnosis of the probability of Alzheimer's disease in a subject patient comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the at least three polypeptide markers are at least three different markers selected from markers 1 to 50 (frequency markers) and markers 51 to 279 (amplitude markers), wherein the diagnosis is based on a comparison and ranking of the frequency and/or amplitude of the at least three polypeptide markers to the same at least three polypeptide markers obtained from control subjects with and without Alzheimer's disease.

Abstract: Method for diagnosis of heart failure, comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and the migration time.

Abstract: The process for the diagnosis of a renal cell carcinoma comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, wherein said polypeptide markers are selected from the markers as characterized in Table 1 by molecular masses and migration times.

Abstract: The invention relates to a method for diagnosing vascular diseases, comprising the step in which the presence, absence or amplitude of at least three polypeptide markers is determined in a urine sample, wherein the polypeptide markers are selected from the markers characterized in table 1 by values for the molecular masses and the migration time.

Abstract: A process for the diagnosis of kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: A method for the diagnosis of a benign or malignant bile duct stricture and/or of a CCC, comprising the step of determining at least three polypeptide markers in a body fluid, wherein the polypeptide marker belongs to those markers which in table 1 and/or table 2 a and/or b are characterized by values for the molecular mass and the migration time.

Abstract: The invention relates to a method for diagnosing vascular diseases, comprising the step in which the presence, absence or amplitude of at least three polypeptide markers is determined in a urine sample, wherein the polypeptide markers are selected from the markers characterized in table 1 by values for the molecular masses and the migration time.

Abstract: The invention relates to a method for diagnosing acute renal failure, comprising the step of determining a presence or absence or amplitude of at least three polypeptide markers in a sample, wherein the polypeptide marker is among the markers characterized in table 1 by values for the molecular weights and the migration time.

Abstract: A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: The process for the diagnosis, early detection and prognosis of the clinical development of autosomal-dominant polycystic kidney disease (ADPKD) comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.

Abstract: A process for the diagnosis of diabetes mellitus comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide markers being selected from the markers characterized by the values for the molecular masses and migration times according to Table 1.

Abstract: The process for the diagnosis of a renal cell carcinoma comprises the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, wherein said polypeptide markers are selected from the markers as characterized in Table 1 by molecular masses and migration times.

Abstract: Provided are a process and a device for the qualitative and/or quantitative determination of a protein and/or peptide pattern of a liquid sample taken from a human or animal body for checking its state. The peptides and proteins of the liquid sample are processed and then subjected to analysis, wherein reference and sample values describing states of a human or animal body as well as deviations and correspondences derived therefrom are established, automatically stored in a data base, and when the protein and/or peptide pattern is again determined, a search for optimum correspondence is automatically performed. In this process, mass components or structural components of the proteins and/or peptides are established and stored.

Abstract: A method for the diagnosis of tubular kidney diseases comprising the step of determining the presence or absence or amplitude of at least three polypeptide markers in a urine sample, the polypeptide marker being selected from the markers characterized in Table 1 by values for the molecular masses and migration times.